R. Terry Dunlay

Founder, President and CEO

Terry has a solid track record of leadership in the life sciences with over 25 years of experience in growing innovative technology companies and building value for customers, shareholders, and employees. Previously, he was co-founder and Executive Vice President of Cellomics, a leading provider of automated cellular analysis instruments, assays, and informatics software that was acquired by Fisher Scientific (now part of Thermo Fisher). At Cellomics, he invented and commercialized the company’s industry leading high content screening products. Prior to Cellomics, Terry was founder and CEO of Biological Detection, Inc. a bio-imaging software company and earlier was Vice President of Biological Detection Systems, Inc. a bio-imaging systems, software, and reagents company that was acquired by Amersham (now part of GE Healthcare). Former affiliations include Cytyc Corporation, Lockheed Martin, and PPG Industries. Terry has a BS and MS in Electrical Engineering and holds numerous patents in the area of cell-based screening instrumentation and informatics.

Dennis Hynson

Chief Financial Officer

Dennis has more than 20 years of experience in the financial management field working in the medical device industry. Dennis served as CFO of LDR Holding, a global leader in development of innovative spinal solutions. In this role, he partnered with the CEO and executive team to significantly grow the business including revenue growth of 10x over his 7 year tenure. He successfully completed a number of financing transactions including private equity placements and various debt instruments. Prior to LDR, Dennis held key financial management positions with Centerpulse Orthopedics as Vice President of Finance and Abbott Spine as Controller. Dennis holds a Bachelor of Science in Finance from the University of Houston and is also a certified public accountant (CPA).

Thomas Duensing, Ph.D.

Chief Technology Officer

Tom has more than 17 years of experience in scientific research, drug discovery and product development in the area of assay, applications and reagent systems. Tom was Senior Director of In Vitro Pharmacology at Tanox, where he built a successful assay development and high throughput screening program which contributed to the advancement of therapeutic monoclonal antibody candidates into clinical development. Prior to Tanox, Tom was Director of Assay Development at Cellomics and has also held research scientist positions at the National Institutes of Health’s Rocky Mountain Labs and Syntex.

Steve Davenport

Vice President, Global Sales

Steve has more than 20 years sales and management experience in the life sciences industry.  Prior to joining IntelliCyt Steve was Vice President European Sales at ProteinSimple, where he oversaw growth of the European sales business from $3.5m to over $10m in 2 years.  Before this Steve was Vice President European Operations at Molecular Devices Corporation, now part of the Medical Technologies division of Danaher Corporation, where he was responsible for the Sales, Support and Service functions throughout Europe and oversaw business growth from $23 to $65m.  Steve was involved in the integration of several acquisitions by Molecular Devices and was also heavily involved in the sale of Molecular Devices to MDS Inc. and subsequently Danaher Corporation.  Steve also spent 13 years at Amersham International, now part of GE Healthcare where he performed multiple sales and business development roles including the market introduction of innovative technologies for Genomics, Proteomics and High Throughput Drug Screening.  Steve holds a BS in Applied Chemistry from the University of Wales Institute of Science and Technology.

Angela K. Schultz

Vice President, Marketing

Angie has over 25-years-experience marketing scientific products in the life sciences and diagnostics industry. Prior to joining IntelliCyt, Angie was Principal and Founder of BioMarketects, a marketing consultancy focused in the life sciences space, and was VP of Marketing for Invitrogen (now Thermo-Fisher) where she was involved in the integration and rebranding of the newly formed  $180M Cellular Analysis Business Unit. She was also VP, Global Marketing and VP, Business Development at BD Biosciences for 14 years where she led the development and marketing efforts for the FACSCalibur product line and was involved in the integration and rebranding of several acquisitions. Angela has an MBA, and a BS in Medical Technology from University of Massachusetts.

Want to learn more or request a demo?

Click Here